Home > Cannabis & Mental Health > THC Potency

THC Potency: Why Today's Marijuana Is a Different Drug

From 4% to 90%: How the Cannabis Supply Changed Everything
By Dr. Ryan S. Sultan, Assistant Professor of Clinical Psychiatry
Columbia University Irving Medical Center
NIH NIDA-Funded Cannabis Researcher | Published in JAMA Network Open & Pediatrics

Contents:
The Potency Timeline | Product-by-Product Breakdown | The Disappearing CBD | Why Potency Matters | Potency and Addiction | Potency and Psychosis | Potency and the Developing Brain | What Parents Need to Know | FAQ

The Potency Timeline: 1970s to Today

The cannabis plant has been selectively bred for maximum THC content over the past five decades. This is the single most important context for understanding modern cannabis research:

Sources: ElSohly et al., Biological Psychiatry, 2016; University of Mississippi Potency Monitoring Program; state testing laboratory data.

To put this in perspective: a person smoking a joint in 1993 at 4% THC and a person hitting a vape pen today at 85% THC are not doing the same thing. That is a 21x difference in the concentration of the psychoactive ingredient. It is the pharmacological equivalent of comparing a glass of beer (5% alcohol) to a glass of pure grain alcohol (95%).

Product-by-Product Breakdown

Flower (Bud)

Traditional smoked cannabis. Average THC has risen from 4% to 15-25%, with premium strains testing 28-33%. Even "mild" flower today is 3-4x stronger than what was available 30 years ago.

Concentrates (Dabs, Wax, Shatter, Live Resin, Rosin)

Cannabis extracts containing 60-90% THC. These products did not meaningfully exist in the consumer market before the 2010s. A single "dab" can deliver more THC in one inhalation than an entire joint of 1990s flower. Concentrates are the fastest-growing product category in legal markets.

Vape Cartridges

Pre-filled cartridges of cannabis oil containing 70-90% THC. Odorless, easily concealable, and the most popular delivery method among adolescents and young adults. The EVALI lung injury outbreak of 2019 was associated primarily with illicit vape cartridges containing vitamin E acetate.

Edibles

THC-infused food products. While dosing per piece can be controlled (typically 5-10mg THC per serving in legal markets), the delayed onset (30-90 minutes) frequently leads to overconsumption. The total THC in a package may be 100-1000mg. A 10mg edible roughly equals smoking a bowl of 15% flower — but the effects last 6-8 hours instead of 2-3.

Delta-8 THC

A cannabinoid synthesized from hemp-derived CBD, technically legal in some states under the 2018 Farm Bill loophole. Delta-8 binds to the same CB1 receptors as delta-9 THC with somewhat lower affinity. Products are largely unregulated, with unpredictable potency, potential contaminants, and no quality standards. Despite marketing as "milder," delta-8 can produce tolerance, dependence, and withdrawal.

The Disappearing CBD

The rise in THC is only half the story. The other half is what disappeared.

CBD (cannabidiol) is a non-intoxicating cannabinoid that may have neuroprotective, anxiolytic, and antipsychotic properties. Research suggests CBD partially counteracts some of THC's harmful effects — particularly its tendency to cause anxiety and psychosis.

Selective breeding has maximized THC and virtually eliminated CBD. Modern recreational cannabis delivers a massive dose of the component that causes harm while removing the component that may offer protection. It is as if beer manufacturers figured out how to make beer with 10x the alcohol and zero water.

Why Potency Matters: The Dose-Response Relationship

Pharmacology has a fundamental principle: dose determines effect. More drug reaching the receptor means a bigger biological response. This is not controversial — it is the basis of all medicine.

For cannabis, higher potency means:

1. More CB1 receptor activation per use episode — the endocannabinoid system is overwhelmed at concentrations far beyond anything it evolved to handle
2. Faster tolerance development — the brain downregulates receptors more aggressively in response to larger stimuli
3. More severe withdrawal — deeper downregulation means a bigger deficit when the drug is removed
4. Greater addiction risk — a stronger stimulus to the reward pathway creates a stronger reinforcement signal
5. Higher psychosis risk — overstimulation of the dopamine system is the leading mechanistic hypothesis for cannabis-induced psychosis
6. More adolescent brain disruption — the developing endocannabinoid system is hijacked at levels that "never existed before in human history" (Hurd 2025)

My own research confirms the dose-response pattern at the population level:

If outcomes worsen with frequency of use, they necessarily also worsen with potency — because a person using 85% THC concentrate daily is getting vastly more THC exposure than someone smoking 4% flower daily.

Potency and Addiction

The addiction rate for cannabis has risen alongside potency — and this is likely not coincidence:

• In the 1990s (3-4% THC), approximately 9% of users developed dependence
• Current estimates suggest 30% of regular users develop cannabis use disorder — though "regular use" now involves 5-20x more THC per session
• Hurd (2025, American Journal of Psychiatry) reports that 1 in 5 people with cannabis use disorder go on to develop schizophrenia, and notes that 37+ weeks of abstinence are needed for full endocannabinoid system recovery — longer than previously thought

Higher potency accelerates the tolerance-dependence-withdrawal cycle:

For more: Is Cannabis Addictive? | Cannabis Withdrawal Timeline

Potency and Psychosis

The relationship between THC potency and psychosis risk is one of the strongest and most consistent findings in cannabis research:

Di Forti et al. (2019, Lancet Psychiatry) studied first-episode psychosis across 11 European cities and found that high-potency cannabis accounted for an estimated 12% of all first-episode psychosis cases across Europe — rising to 30% in London and 50% in Amsterdam, where high-potency cannabis dominates the market.

The potency threshold matters: the risk inflection point appears to be around 10% THC. Below that, psychosis risk is elevated but moderate. Above it, risk accelerates sharply. Most commercially available cannabis today — in both legal and illegal markets — exceeds this threshold.

For the full analysis: Cannabis and Psychosis: What the Research Shows

Potency and the Developing Brain

The adolescent brain uses its endocannabinoid system — specifically CB1 receptors — to guide development. THC overstimulates these receptors. Higher potency means greater overstimulation during a critical window.

Key data from Hurd (2025):

• PET imaging shows CB1 receptor density drops approximately 20% in chronic users
• In adults, CB1 receptor density recovers within weeks of abstinence
• In adolescents, the structural changes caused by THC during development may be permanent because the drug was present during construction — the pruning that happened too early cannot be reversed
• Current THC exposure levels "overstimulate cannabinoid receptors to a degree that never existed before in human history"

The Dunedin longitudinal study (Meier 2012) — which found the 8 IQ point decline in persistent adolescent-onset users — was conducted when THC averaged approximately 8-10%. Today's adolescents are using products 3-9x stronger than what produced that irreversible cognitive decline.

For the full science: Cannabis and the Teenage Brain

What Parents Need to Know About Modern Cannabis Products

Vape pens are the biggest risk for teens

Vape pens are nearly odorless, easily concealed (they look like USB drives or regular e-cigarettes), and deliver 70-90% THC. They are the most common cannabis delivery method among adolescents. A teen using a vape pen is getting 20x the THC their parent got from a joint in the 1990s.

"I smoked pot and I turned out fine" no longer applies

If you used cannabis in the 1980s or 1990s, you were using a fundamentally different product. Comparing your experience to your teenager's is like comparing a glass of beer to a bottle of liquor. The pharmacology has changed.

Edibles look like regular candy

THC gummies, chocolates, and baked goods are indistinguishable from regular food products. A single package may contain 100-1000mg of THC — enough for 10-100 doses. Accidental overconsumption, including by younger children, is an increasing emergency department presentation.

Delta-8 is marketed as "legal weed" to minors

Delta-8 THC products are sold in gas stations, convenience stores, and online — often to minors in states where recreational cannabis is illegal. They are unregulated, untested, and psychoactive. Do not assume your teen isn't using THC just because recreational cannabis is illegal in your state.

Frequently Asked Questions

If I use less of a stronger product, isn't that the same thing?

In theory, yes — if you could precisely control your dose. In practice, no one titrates a dab the way a pharmacist measures a medication. Inhalation delivers THC to the brain in seconds, and the difference between "a little" and "too much" of an 85% concentrate is tiny. Additionally, high-potency products produce faster tolerance, meaning users quickly escalate to larger doses.

Are concentrates more addictive than flower?

Yes, likely. Higher potency means stronger reward pathway activation, faster tolerance, and more severe withdrawal — the three pillars of addiction liability. While no RCT has directly compared concentrate vs. flower addiction rates, the pharmacological principles are clear, and clinicians report more rapid development of CUD with concentrate use.

Is high-CBD cannabis safer?

Probably, to some degree. CBD may partially counteract THC's anxiogenic and psychotogenic effects. A product with 10% THC and 10% CBD (1:1 ratio) is likely less harmful than a product with 25% THC and no CBD. However, "safer" does not mean "safe." High-CBD cannabis still contains THC and still carries risks — just potentially reduced ones.

Why do dispensaries sell such high-potency products?

Market incentives. Consumers (especially experienced users with tolerance) prefer stronger products — they perceive better value per dollar. Dispensaries stock what sells. State regulations have generally not capped potency, though some jurisdictions are beginning to consider it. The market has optimized for maximum intoxication, not minimum harm.

Should there be a potency cap?

This is a policy question, not a medical one. From a public health perspective, the evidence supports that higher potency carries higher risk. Vermont and Connecticut have considered potency caps. Some researchers have suggested treating high-potency cannabis products the way we treat high-proof alcohol — with different regulations, taxes, and warnings. Whether this would reduce harm or simply drive consumers to illegal markets is debated.